Cisplatin, vindesine, mitomycin-c and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study

Anticancer Research

Volumn 20, Issue 3 B, 2000, Pages 1985-1990

  Recchia, Francesco ^a,b,d   Sica, Gigliola ^c   De Filippis, Sandro ^a   Rosselli, Michele ^b   Saggio, Gaetano ^a   Guerriero, Gabriele ^b   Pompili, Pierluigi ^b   Rea, Silvio ^d  

^a Ospedale Civile   (Italy)

^b CROFI Fondazione Ferri Monterotondo   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d NONE

Author keywords

13 cis retinoic acid; Cisplatin; Mitomycin c; Non small cell lung cancer; Vindesine

Indexed keywords

CISPLATIN; ISOTRETINOIN; MITOMYCIN C; VINDESINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERLIPIDEMIA; ILEUS; INFECTION; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FATTY LIVER; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; ISOTRETINOIN; LEUKOPENIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; NERVOUS SYSTEM DISEASES; PILOT PROJECTS; REMISSION INDUCTION; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VINDESINE;

EID: 0033883118     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. th ed. Philadelphia, Lippincott-Raven, 1997: 858-911.
2. Rapp E, Pater J, Willan A, Cormier Y, Murray N, Evans WK, Hodson ID, Clark AD, Feld R, Arnold AM, Ayoub JI, Wilson KS, Latreille J, Wierzbicki RF and Hill DP: Chemotherapy can prolong survival in patients with non-small cell lung cancer: report of a Canadian multicenter randomised trial. J Clin Oncol 6: 633-41, 1988.
3. Bunn PA Jr: The expanding role of cisplatin in the treatment of non-small cell lung cancer. Semin Oncol 16: 10-21 (suppl 6), 1989.
4. Joss RA, Cavalli F, Goldhirsch A, Mermillod B and Brunner KW: New agents in non-small-cell lung cancer. Cancer Treat Rev 11: 205-36, 1984.
5. Sporn MB, Dunlop NM, Newton DL and Smith JM: Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35: 1332-1338, 1976.
6. Srikland S and Mahdavi V: The induction of differentiation in teratocarcinoma stem cells by retinoic acid. Cell 15: 393-403, 1980.
7. Lotan R: Effects of vitamin A and its analogues (retinoids) on normal and neoplastic cells. Biochim Biophys Acta 60: 533-91, 1980.
8. Sporn MB and Roberts AB: Role of retinoids in differentiation and carcinogenesis. Cancer Res 43: 3034-3040, 1983.
9. Lippman SM, Kessler JF and Meyskens FL Jr: Retinoids as preventive and therapeutic anticancer agents. Cancer Treat Rep 71: 391-405, 493-515, 1987.
10. Farina AR, Coppa A, Tiberio, Tacconelli A, Turco A, Colletta G, Gulino A and Mackay AR: Transforming growth factor-beta1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. Int J Cancer 75: 721-30, 1998.
11. Huang ME, Ye YC, Chen SR, Zhan JC, Gu LJ, Zhao L, Zie JX, Shen ZX and Wang ZX: Use of all trans retinoic acid in the treatment of acute promyelocytic leukemia. Clinical results. Blood 76: 567-572, 1988.
12. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, Schantz SP, Kramer AM, Lotan R, Peters U et al: Prevention of secondary primary tumor with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J of Med 323: 795-801, 1990.
13. Pastorino U, Infante M, Maioli M, Chiesa G, Buyse M, Firket P, Rosmentz N, Clerici M, Soresi E, Valente M, Belloni PA and Ravasi G: Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 11: 1216-1222, 1993.
14. Spear G, Paulnock D, Jordan R, Meltzer DM, Merritt JA and Borden EC: Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo beta-interferon. Clin Exper Immunolo 69: 107-115, 1987.
15. Prabhala RH, Garenwal HSS, Hicks MJ, Sampliner RE and Watson RR: The effects of 13-cis-Retinoic acid and beta-carotene on cellular immunity in humans. Cancer 67: 1556-1560, 1991.
16. WHO. Handbook for Reporting Results of cancer treatment. (Offset publication 48). WHO, Geneva, 1979.
17. Gehan EA: The determination of the number of patients required in a preliminary and follow up trial of a new chemotherapy agent. J Chron Dis 13: 346-353, 1961.
18. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Ass 53: 457-481, 1958.
19. Recchia F, Rea S, Corrao G, Fingerhut A, Frati L: Sequential chemotherapy, beta interferon, retinoids and tamoxifen in the treatment of metastatic breast cancer. A pilot study. European Journal of Cancer 31 A: 1887-8, 1995.
20. Recchia F, Sica G, De Filippis S, Rea S and Frati L: Combined chemotherapy and differentiation therapy in the treatment of advanced non-small-cell lung cancer. Anticancer Research 17: 3761-3766, 1997.
21. Gralla RT and Kors MG: Chemotherapy in non-small-cell lung cancer. Results of recent trials. Semin Oncol 15: 2-5, 1988.
22. Non-small-cell lung cancer collaborative group: chemotherapy in non-small-cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311: 899-909, 1995.
23. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA and Vogl S: A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 4: 14-22, 1986.
24. Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tormey DC, Harris J, Comis R and Glick J: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 7: 1602-1613, 1989.
25. Kourousis C, Androulakis N, Kakolyris S, Souglakos J, Maltezakis G, Metaxaris G, Chalkiadakis G. Samonis G. Vlachonikolis J and Georgoulias V: First-line treatment of advanced non-small cell lung carcinoma with docetaxel and vinorelbine. Cancer S3: 2083-2090, 1998.
26. Zalcberg J, Millward M, Bishop J, McKeage M, Zimet A, Toner G, Friedlander M, Barter C, Rischin D, Loret C, James R, Bougon N, Berille J. Phase II study of docetaxel in advanced non-small-cell lung cancer. J Clin Oncol 16: 1948-1953, 1998.
27. Giaccone G, Splinter TA, Debruyne C, Kho GS, Lianes P, van Zandwijk N, Pennucci MC, Scagliotti G, van Meerbeek CK, van Hoesel Q, Curran D, Sahmoud T and Postmus PE: Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 16: 2133-2141, 1998.
28. Fidler IJ and Poste G: The cellular heterogeneity of malignant neoplasms: implication for adjuvant chemotherapy. Sem Oncol 12: 207-22, 1985.
29. Lotan R, Xu XC, Lippman SM, Ro JY, Lee JS, Lee JJ and Hong WK: Suppression of retinoic acid receptor-ß in premalignant oral lesions and its up-regulation by isotretinoin. N Eng J Med 332: 1405-410, 1995.
30. Marsh W and Center MS: Dimethylsulfoxide, retinoic acid and 12-O-tetra-decanoylphorbol-13-acetate induce a selective decrease in the phosphorylation of P150, a surface membrane phosphoprotein of HL-60 cells resistant to Adriamycin. Biochem Biophys Res Commun 138: 9-16, 1986.
31. Long DM: Capillary ultrastructure in human metastatic brain tumors. J Nerosurg 51: 53-8, 1979.